MedTrace Logo

Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults

NCT04862338 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2023-01-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the physiological and/or biological actions of nicotinamide mononucleotide (NMN-C) in healthy adults receiving a repeated-dose over the course of 28 days by studying the tolerance and pharmacodynamics of this product.

Conditions

  • Healthy Volunteers

Interventions

DIETARY_SUPPLEMENT

Nicotinamide mononucleotide (NMN-C)

Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total

Sponsors & Collaborators

  • CEN Biotech

    collaborator INDUSTRY

  • LGD

    collaborator INDUSTRY

  • Seneque SA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2021-09-08
Completion
2022-04-04

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04862338 on ClinicalTrials.gov